Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
52.76
+0.01 (0.02%)
At close: Apr 28, 2026, 4:00 PM EDT
52.71
-0.05 (-0.09%)
After-hours: Apr 28, 2026, 4:40 PM EDT
Soleno Therapeutics Employees
Soleno Therapeutics had 182 employees as of December 31, 2025. The number of employees increased by 90 or 97.83% compared to the previous year.
Employees
182
Change (1Y)
90
Growth (1Y)
97.83%
Revenue / Employee
$1,046,181
Profits / Employee
$112,500
Market Cap
2.73B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| ADMA Biologics | 647 |
| Beam Therapeutics | 511 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Immunome | 177 |
| Disc Medicine | 155 |
| IDEAYA Biosciences | 145 |
SLNO News
- 13 days ago - Folia Health Launches “BRAVE-PWS” Study to Better Understand the Real-World Experience of Prader-Willi Syndrome Caregivers - GlobeNewsWire
- 13 days ago - Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders? - PRNewsWire
- 19 days ago - SOLENO THERAPEUTICS, INC. (SLNO) DEADLINE ALERT Bernstein Liebhard LLP Reminds Soleno Therapeutics, Inc. Investors of Upcoming Deadline - GlobeNewsWire
- 21 days ago - Soleno withdraws EU rare disease drug application ahead of Neurocrine takeover - Reuters
- 22 days ago - Neurocrine to Buy Soleno for $2.9 Billion - WSJ
- 22 days ago - Neurocrine to buy Soleno Therapeutics for $2.9 billion - Reuters
- 22 days ago - Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio - PRNewsWire
- 27 days ago - Soleno (SLNO) Sued After DCCR Launch Setback, Share Drop-- Hagens Berman - PRNewsWire